Skip to main content

Table 3 Comparison between prostaglandin analogue use and none, in both POAG and PACG groups

From: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in the aqueous humour of patients with primary angle closure glaucoma - a quantitative study

 

Prostaglandin analogue use

No prostaglandin analogue use

P-value

POAG

n

17

11

 

Total protein (mg/ml)

0.67 ± 0.36

0.61 ± 0.49

0.404

MMP2 (ng/ml)

37.84 ± 23.53

32.08 ± 17.36

0.689

MMP3 (ng/ml)

14.88 ± 15.38

10.78 ± 16.21

0.063

TIMP1 (ng/ml)

32.18 ± 22.96

36.29 ± 41.44

0.742

TIMP2 (ng/ml)

61.56 ± 62.17

37.80 ± 29.16

0.375

PACG

n

9

7

 

Total protein (mg/ml)

0.47 ± 0.12

0.39 ± 0.13

0.899

MMP2 (ng/ml)

25.28 ± 12.73

29.07 ± 19.79

0.837

MMP3 (ng/ml)

20.02 ± 45.69

4.31 ± 2.48

0.692

TIMP1 (ng/ml)

43.81 ± 44.14

29.84 ± 14.77

0.681

TIMP2 (ng/ml)

47.52 ± 40.11

30.85 ± 22.33

0.408